Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk A/S

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

THE STRONG PERFORMANCE OF WEGOVY AND CONTINUED GROWTH IN INTERNATIONAL OPERATIONS HAVE LED US TO RAISE OUR 2026 GUIDANCE FOR BOTH ADJUSTED SALES AND

NOVO NORDISK'S ADJUSTED OPERATING PROFIT REACHED DKK 32,858 MILLION IN Q1 2026

BAGSVRD, DENMARK, 5 MAY 2026  ON 4 FEBRUARY 2026, NOVO NORDISK INITIATED A SHARE REPURCHASE PROGRAMME IN ACCORDANCE WITH ARTICLE 5 OF REGULATION NO 596/2014 OF THE EUROPEAN PARLIAMENT AND COUNCIL OF 16 APRIL 2014 (MAR) AND THE COMMISSION DELEGATED REGULATION (EU) 2016/1052 OF 8 MARCH 2016 (THE "SAFE HARBOUR RULES"). THIS PROGRAMME IS PART OF THE OVERALL SHARE REPURCHASE PROGRAMME OF UP TO DKK 15 BILLION TO BE EXECUTED DURING A 12-MONTH PERIOD BEGINNING 4 FEBRUARY 2026.

NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME

PERTH, AUSTRALIA, APRIL 30, 2026 (GLOBE NEWSWIRE) -- NOVO RESOURCES CORP.(NOVO OR THE COMPANY) (ASX: NVO & NVOO) (TSX: NVO) (OTCQX: NSRPF) IS PLEASED TO INVITE SHAREHOLDERS AND INVESTORS TO A WEBINAR PRESENTATION BY EXECUTIVE CO-CHAIRMAN MIKE SPREADBOROUGH COVERING A DISCUSSION ON THE COMPANY'S MARCH 2026 QUARTERLY ACTIVITIES AND OUTLOOK. THE LINK TO THE WEBINAR IS INCLUDED BELOW.

WEBINAR INVITATION: NOVO RESOURCES CORP. EXECUTIVE CO-CHAIRMAN TO DISCUSS THE MARCH QUARTER ACTIVITIES AND OUTLOOK

ANALYSES OF THE HIGHER DOSE OF WEGOVY (SEMAGLUTIDE 7.2 MG) AND WEGOVY PILL (ORAL SEMAGLUTIDE 25 MG) SHOW HOW FAST AND HOW MUCH SUSTAINED WEIGHT LOSS PEOPLE WHO RESPONDED EARLY TO TREATMENT ACHIEVED WEGOVY (SEMAGLUTIDE 2.4 MG AND 7.2 MG) CLINICAL AND REAL-WORLD DATA EXPLORING ITS ROLE IN MANAGING MENOPAUSAL SYMPTOMS, INCLUDING WEIGHT GAIN AND MIGRAINE, AND LOWERING CARDIOVASCULAR RISK DATA ON NEXT-GENERATION OBESITY PIPELINE, INCLUDING THE ADVANCED COMBINED AMYLIN AND GLP-1 RECEPTOR ANALOGUES BAGSVRD, DENMARK, 28 APRIL 2026  NOVO NORDISK WILL PRESENT NEW CLINICAL DATA AND REAL-WORLD EVIDENCE AT THE EUROPEAN CONGRESS ON OBESITY, 1215 MAY IN ISTANBUL, TURKEY. THE FULL DATA, 52 ABSTRACTS, SPAN WEGOVY (SEMAGLUTIDE 2.4 MG), HIGHER-DOSE WEGOVY (SEMAGLUTIDE 7.2 MG), WEGOVY PILL (ORAL SEMAGLUTIDE 25 MG), AND CAGRISEMA (CAGRILINTIDE 2.4 MG/SEMAGLUTIDE 2.4 MG), AN INVESTIGATIONAL FIRST-IN-CLASS COMBINATION OF A GLP-1 RECEPTOR AGONIST AND A LONG-ACTING AMYLIN ANALOGUE.

NOVO NORDISK TO PRESENT NEW DATA ON WEGOVY, WOMEN WITH OBESITY AND NEXT-GENERATION WEIGHT LOSS TREATMENTS AT EUROPEAN CONGRESS ON OBESITY

BAGSVRD, DENMARK, 27 APRIL 2026  ON 4 FEBRUARY 2026, NOVO NORDISK INITIATED A SHARE REPURCHASE PROGRAMME IN ACCORDANCE WITH ARTICLE 5 OF REGULATION NO 596/2014 OF THE EUROPEAN PARLIAMENT AND COUNCIL OF 16 APRIL 2014 (MAR) AND THE COMMISSION DELEGATED REGULATION (EU) 2016/1052 OF 8 MARCH 2016 (THE "SAFE HARBOUR RULES"). THIS PROGRAMME IS PART OF THE OVERALL SHARE REPURCHASE PROGRAMME OF UP TO DKK 15 BILLION TO BE EXECUTED DURING A 12-MONTH PERIOD BEGINNING 4 FEBRUARY 2026.

PIONEER TEENS IS THE FIRST CLINICAL TRIAL OF AN ORAL GLP-1 IN CHILDREN & ADOLESCENTS 1017 YEARS WITH TYPE 2 DIABETES, ADDRESSING A SIGNIFICANT UNMET NEED

NOVO NORDISK'S ORAL SEMAGLUTIDE DEMONSTRATES POTENTIAL TO BE THE FIRST ORAL GLP-1 RA THERAPY FOR CHILDREN AND ADOLESCENTS WITH TYPE 2 DIABETES

BAGSVRD, DENMARK, 20 APRIL 2026 ON 4 FEBRUARY 2026, NOVO NORDISK INITIATED A SHARE REPURCHASE PROGRAMME IN ACCORDANCE WITH ARTICLE 5 OF REGULATION NO 596/2014 OF THE EUROPEAN PARLIAMENT AND COUNCIL OF 16 APRIL 2014 (MAR) AND THE COMMISSION DELEGATED REGULATION (EU) 2016/1052 OF 8 MARCH 2016 (THE "SAFE HARBOUR RULES"). THIS PROGRAMME IS PART OF THE OVERALL SHARE REPURCHASE PROGRAMME OF UP TO DKK 15 BILLION TO BE EXECUTED DURING A 12-MONTH PERIOD BEGINNING 4 FEBRUARY 2026.

PERTH, AUSTRALIA, APRIL 14, 2026 (GLOBE NEWSWIRE) -- NOVO RESOURCES CORP.(NOVO OR THE COMPANY) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) IS PLEASED TO ANNOUNCE THAT MR. ROHAN WILLAMS, AN EXPERIENCED EXPLORATION GEOLOGIST, HAS ACCEPTED THE POSITION OF NOVO'S GENERAL MANAGER OF EXPLORATION EFFECTIVE 15 APRIL 2026.

NOVO RESOURCES STRENGTHENS EXPLORATION LEADERSHIP WITH APPOINTMENT OF EXPERIENCED GEOLOGIST MR. ROHAN WILLIAMS

BAGSVRD, DENMARK, 14 APRIL 2026  NOVO NORDISK TODAY ANNOUNCED A STRATEGIC PARTNERSHIP WITH OPENAI THAT WILL PLACE NOVO NORDISK AT THE FOREFRONT OF AI TRANSFORMATION IN HEALTHCARE AND HELP THE COMPANY BRING NEW AND BETTER TREATMENT OPTIONS TO PATIENTS FASTER.

NOVO NORDISK AND OPENAI PARTNER TO TRANSFORM HOW MEDICINES ARE DISCOVERED AND DELIVERED

BAGSVRD, DENMARK, 13 APRIL 2026 ON 4 FEBRUARY 2026, NOVO NORDISK INITIATED A SHARE REPURCHASE PROGRAMME IN ACCORDANCE WITH ARTICLE 5 OF REGULATION NO 596/2014 OF THE EUROPEAN PARLIAMENT AND COUNCIL OF 16 APRIL 2014 (MAR) AND THE COMMISSION DELEGATED REGULATION (EU) 2016/1052 OF 8 MARCH 2016 (THE "SAFE HARBOUR RULES"). THIS PROGRAMME IS PART OF THE OVERALL SHARE REPURCHASE PROGRAMME OF UP TO DKK 15 BILLION TO BE EXECUTED DURING A 12-MONTH PERIOD BEGINNING 4 FEBRUARY 2026.

BAGSVRD, DENMARK, 7 APRIL 2026  ON 4 FEBRUARY 2026, NOVO NORDISK INITIATED A SHARE REPURCHASE PROGRAMME IN ACCORDANCE WITH ARTICLE 5 OF REGULATION NO 596/2014 OF THE EUROPEAN PARLIAMENT AND COUNCIL OF 16 APRIL 2014 (MAR) AND THE COMMISSION DELEGATED REGULATION (EU) 2016/1052 OF 8 MARCH 2016 (THE "SAFE HARBOUR RULES"). THIS PROGRAMME IS PART OF THE OVERALL SHARE REPURCHASE PROGRAMME OF UP TO DKK 15 BILLION TO BE EXECUTED DURING A 12-MONTH PERIOD BEGINNING 4 FEBRUARY 2026.

NOVO NORDISK A/S  SHARE REPURCHASE PROGRAMME

THROUGH EXPANDED COLLABORATION WITH NOVO NORDISK, ELIGIBLE MED+ MEMBERS CAN NOW SAVE UP TO $1,200 PER YEAR ON WEGOVY, INCREASING AFFORDABLE ACCESS TO FDA-APPROVED GLP-1 TREATMENT LEVERAGING WEIGHT WATCHERS' INTEGRATED CARE PLATFORM THROUGH EXPANDED COLLABORATION WITH NOVO NORDISK, ELIGIBLE MED+ MEMBERS CAN NOW SAVE UP TO $1,200 PER YEAR ON WEGOVY, INCREASING AFFORDABLE ACCESS TO FDA-APPROVED GLP-1 TREATMENT LEVERAGING WEIGHT WATCHERS' INTEGRATED CARE PLATFORM

WEIGHT WATCHERS ANNOUNCES BEST IN MARKET SELF-PAY WEGOVY PRICING FOR MED+ MEMBERS AND THE LAUNCH OF PREFERRED SUBSCRIPTION PRICING FOR WEGOVY VIA NOVOCARE

BAGSVRD, DENMARK, 30 MARCH 2026  ON 4 FEBRUARY 2026, NOVO NORDISK INITIATED A SHARE REPURCHASE PROGRAMME IN ACCORDANCE WITH ARTICLE 5 OF REGULATION NO 596/2014 OF THE EUROPEAN PARLIAMENT AND COUNCIL OF 16 APRIL 2014 (MAR) AND THE COMMISSION DELEGATED REGULATION (EU) 2016/1052 OF 8 MARCH 2016 (THE "SAFE HARBOUR RULES"). THIS PROGRAMME IS PART OF THE OVERALL SHARE REPURCHASE PROGRAMME OF UP TO DKK 15 BILLION TO BE EXECUTED DURING A 12-MONTH PERIOD BEGINNING 4 FEBRUARY 2026.

500 - INTERNAL SERVER ERROR. SERVER ERROR 500 - INTERNAL SERVER ERROR.

ARTICLES OF ASSOCIATION FOR NOVO NORDISK A/S 2026

FDA HAS APPROVED AWIQLI INJECTION 700 UNITS/ML, THE FIRST AND ONLY ONCE-WEEKLY, LONG-ACTING BASAL INSULIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE ..

NOVO NORDISK A/S: AWIQLI APPROVED IN THE US, THE FIRST AND ONLY ONCE-WEEKLY BASAL INSULIN TREATMENT FOR ADULTS WITH TYPE 2 DIABETES

BAGSVRD, DENMARK, 26 MARCH 2026 TODAY, NOVO NORDISK A/S HELD ITS ANNUAL GENERAL MEETING. AT THE ANNUAL GENERAL MEETING, LARS REBIEN SRENSEN, CHAIR OF THE BOARD OF DIRECTORS, STATED: 2025 WAS A YEAR OF PROFOUND TRANSFORMATION FOR NOVO NORDISK AND THIS EXTRAORDINARY PERIOD HAS TAUGHT US SOME IMPORTANT LESSONS.

RESOLUTIONS FROM THE ANNUAL GENERAL MEETING OF NOVO NORDISK A/S

BAGSVRD, DENMARK, 23 MARCH 2026  ON 4 FEBRUARY 2026, NOVO NORDISK INITIATED A SHARE REPURCHASE PROGRAMME IN ACCORDANCE WITH ARTICLE 5 OF REGULATION NO 596/2014 OF THE EUROPEAN PARLIAMENT AND COUNCIL OF 16 APRIL 2014 (MAR) AND THE COMMISSION DELEGATED REGULATION (EU) 2016/1052 OF 8 MARCH 2016 (THE "SAFE HARBOUR RULES"). THIS PROGRAMME IS PART OF THE OVERALL SHARE REPURCHASE PROGRAMME OF UP TO DKK 15 BILLION TO BE EXECUTED DURING A 12-MONTH PERIOD BEGINNING 4 FEBRUARY 2026.

AVERAGE WEIGHT LOSS OF ~21% AT 72 WEEKS IN ADULTS WITH OBESITY IF ALL PATIENTS STAYED ON TREATMENT* WITH WEGOVY  HD (~19% REGARDLESS OF WHETHER PATIENTS STAYED ON TREATMENT**) IN THE STEP UP TRIAL1 IN THE STEP UP TRIAL, ABOUT ONE IN THREE TRIAL PARTICIPANTS TAKING WEGOVY HD ACHIEVED 25% WEIGHT LOSS OR HIGHER1 THIS APPROVAL FOR WEGOVY FURTHER EXPANDS ITS ALREADY ROBUST LABEL INCLUSIVE OF MULTIPLE FORMULATIONS, INCLUDING WEGOVY PILL, AND INDICATIONS NOT AVAILABLE WITH OTHER GLP-1 WEIGHT LOSS MEDICINES PLAINSBORO, N.J., MARCH 19, 2026 /PRNEWSWIRE/ --NOVO NORDISK TODAY ANNOUNCED US FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF A NEW HIGHER DOSE OF WEGOVY, WEGOVY HD (SEMAGLUTIDE) INJECTION 7.2 MG, WHICH DEMONSTRATED SUBSTANTIAL WEIGHT LOSS IN ADULTS WITH OBESITY IN THE STEP UP TRIAL.1,2 WEGOVY  HD CAN BE USED ALONG WITH A REDUCED CALORIE DIET AND INCREASED PHYSICAL ACTIVITY TO HELP ADULTS WITH OBESITY LOSE WEIGHT AND KEEP IT OFF, PROVIDED THEY HAVE TOLERATED THE 2.4 MG DOSAGE FOR AT LEAST 4 WEEKS AND ADDITIONAL WEIGHT REDUCTION IS CLINICALLY INDICATED.

FDA APPROVES NOVO NORDISK'S NEW WEGOVY HD INJECTION, DELIVERING THE HIGHEST WEIGHT LOSS TO DATE FOR A WEGOVY INJECTION, ADDING TO ITS ALREADY EXPANSIVE CLINICAL PROFILE

WEGOVY HD DEMONSTRATED A MEAN WEIGHT LOSS OF 20.7%1, AND AROUND ONE-THIRD OF PATIENTS ACHIEVED 25% OR GREATER WEIGHT LOSS IN THE STEP UP TRIAL FIRST US FDA APPROVAL OF A GLP-1 TREATMENT UNDER THE COMMISSIONER'S NATIONAL PRIORITY VOUCHER PILOT PROGRAMME, FOR PRODUCTS ADDRESSING CRITICAL US NATIONAL HEALTH PRIORITIES WEGOVY HD COMPLEMENTS WEGOVY 2.4 MG, WHICH IS ALREADY APPROVED IN THE US FOR WEIGHT MANAGEMENT AND CARDIOVASCULAR RISK REDUCTION NOVO NORDISK EXPECTS TO LAUNCH WEGOVY HD IN THE US IN APRIL 2026 BAGSVRD, DENMARK, 19 MARCH 2026  NOVO NORDISK TODAY ANNOUNCED THAT THE US FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED WEGOVY HD (ONCE-WEEKLY INJECTABLE SEMAGLUTIDE 7.2 MG) TO REDUCE EXCESS BODY WEIGHT AND MAINTAIN WEIGHT REDUCTION LONG-TERM. THE FDA AWARDED A COMMISSIONER'S NATIONAL PRIORITY VOUCHER FOR WEGOVY HD, ACCELERATING ITS REVIEW AND UNDERSCORING ITS POTENTIAL TO ADDRESS CRITICAL PATIENT NEEDS AND NATIONAL HEALTH PRIORITIES IN THE US.

NOVO NORDISK A/S: WEGOVY HD (SEMAGLUTIDE 7.2 MG) APPROVED IN THE US, PROVIDING 20.7% MEAN WEIGHT LOSS

LOS ANGELES, MARCH 17, 2026 (GLOBE NEWSWIRE) -- THE PORTNOY LAW FIRM ADVISES NOVO NORDISK A/S (NOVO NORDISK" OR THE "COMPANY") (NYSE:NVO) INVESTORS THAT THE FIRM HAS INITIATED AN INVESTIGATION INTO POSSIBLE SECURITIES FRAUD, AND MAY FILE A CLASS ACTION ON BEHALF OF INVESTORS.

NOVO NORDISK A/S INVESTIGATED BY THE PORTNOY LAW FIRM

BAGSVRD, DENMARK, 16 MARCH 2026  ON 4 FEBRUARY 2026, NOVO NORDISK INITIATED A SHARE REPURCHASE PROGRAMME IN ACCORDANCE WITH ARTICLE 5 OF REGULATION NO 596/2014 OF THE EUROPEAN PARLIAMENT AND COUNCIL OF 16 APRIL 2014 (MAR) AND THE COMMISSION DELEGATED REGULATION (EU) 2016/1052 OF 8 MARCH 2016 (THE "SAFE HARBOUR RULES"). THIS PROGRAMME IS PART OF THE OVERALL SHARE REPURCHASE PROGRAMME OF UP TO DKK 15 BILLION TO BE EXECUTED DURING A 12-MONTH PERIOD BEGINNING 4 FEBRUARY 2026.

NEW YORK, MARCH 12, 2026 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF NOVO NORDISK A/S ("NOVO NORDISK" OR THE "COMPANY") (NYSE: NVO). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF NOVO NORDISK A/S - NVO

TOTAL INCOME AND INVESTMENT RETURNS IN 2025 WERE DKK 21 BILLION (2.8 BILLION). FOR 2025, TOTAL INCOME AND INVESTMENT RETURNS CONSISTED OF INCOME FROM DIVIDENDS FROM THE NOVO GROUP COMPANIES (DKK 15 BILLION OR 2.0 BILLION) AND RETURNS FROM THE INVESTMENT ASSETS PORTFOLIO 1 (DKK 5.8 BILLION OR 0.8 BILLION).

Novo Nordisk A/S

NVO

Price

Financial Reports

No items found.

Press Releases

Novo Nordisk A/S

NVO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NVO